In turn, we used the ERα levels in BC cells as a novel pharmacological target to screen a library of 1018 Food and Drug Administration (FDA)-approved drugs with the aim of identifying the compounds that can modify ERα protein levels and inhibit BC cell proliferation [2,17,18,19]. The gene discussed is ESR1; the disease is breast cancer.